Maintenance etidronate in the prevention of malignancy-associated hypercalcemia

J. H. Schiller, P. Rasmussen, A. B. Benson, R. S. Witte, R. S. Bockman, H. A. Harvey, E. S. Siris, D. L. Citrin, F. A. Greco, J. L. Stock

Research output: Contribution to journalArticle

Abstract

Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40%) of 25 etidronate-treated patients and 17 (46%) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.

Original languageEnglish (US)
Pages (from-to)963-966
Number of pages4
JournalArchives of Internal Medicine
Volume147
Issue number5
DOIs
StatePublished - Aug 3 1987

Fingerprint

Etidronic Acid
Hypercalcemia
Maintenance
Neoplasms
Placebos
Recurrence
Therapeutic Uses
Calcium
Control Groups
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Schiller, J. H., Rasmussen, P., Benson, A. B., Witte, R. S., Bockman, R. S., Harvey, H. A., ... Stock, J. L. (1987). Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Archives of Internal Medicine, 147(5), 963-966. https://doi.org/10.1001/archinte.147.5.963
Schiller, J. H. ; Rasmussen, P. ; Benson, A. B. ; Witte, R. S. ; Bockman, R. S. ; Harvey, H. A. ; Siris, E. S. ; Citrin, D. L. ; Greco, F. A. ; Stock, J. L. / Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. In: Archives of Internal Medicine. 1987 ; Vol. 147, No. 5. pp. 963-966.
@article{54ca0417482949b686929ff742e3d3bd,
title = "Maintenance etidronate in the prevention of malignancy-associated hypercalcemia",
abstract = "Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40{\%}) of 25 etidronate-treated patients and 17 (46{\%}) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.",
author = "Schiller, {J. H.} and P. Rasmussen and Benson, {A. B.} and Witte, {R. S.} and Bockman, {R. S.} and Harvey, {H. A.} and Siris, {E. S.} and Citrin, {D. L.} and Greco, {F. A.} and Stock, {J. L.}",
year = "1987",
month = "8",
day = "3",
doi = "10.1001/archinte.147.5.963",
language = "English (US)",
volume = "147",
pages = "963--966",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "5",

}

Schiller, JH, Rasmussen, P, Benson, AB, Witte, RS, Bockman, RS, Harvey, HA, Siris, ES, Citrin, DL, Greco, FA & Stock, JL 1987, 'Maintenance etidronate in the prevention of malignancy-associated hypercalcemia', Archives of Internal Medicine, vol. 147, no. 5, pp. 963-966. https://doi.org/10.1001/archinte.147.5.963

Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. / Schiller, J. H.; Rasmussen, P.; Benson, A. B.; Witte, R. S.; Bockman, R. S.; Harvey, H. A.; Siris, E. S.; Citrin, D. L.; Greco, F. A.; Stock, J. L.

In: Archives of Internal Medicine, Vol. 147, No. 5, 03.08.1987, p. 963-966.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Maintenance etidronate in the prevention of malignancy-associated hypercalcemia

AU - Schiller, J. H.

AU - Rasmussen, P.

AU - Benson, A. B.

AU - Witte, R. S.

AU - Bockman, R. S.

AU - Harvey, H. A.

AU - Siris, E. S.

AU - Citrin, D. L.

AU - Greco, F. A.

AU - Stock, J. L.

PY - 1987/8/3

Y1 - 1987/8/3

N2 - Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40%) of 25 etidronate-treated patients and 17 (46%) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.

AB - Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, >11.5 mg/dL [>2.87 mmol/L]). Ten (40%) of 25 etidronate-treated patients and 17 (46%) of 37 placebo-treated patients had recurrence of hypercalcemia within 150 days. Although patients taking etidronate had a longer time to the development of hypercalcemia (median, 55 days vs 28 days), this was not significantly different from the control group. The high attrition rate in this trial from hypercalcemia and other malignancy-related causes represents a major difficulty in conducting studies with agents that may require prolonged administration before producing a therapeutic effect.

UR - http://www.scopus.com/inward/record.url?scp=0023215972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023215972&partnerID=8YFLogxK

U2 - 10.1001/archinte.147.5.963

DO - 10.1001/archinte.147.5.963

M3 - Article

C2 - 3107487

VL - 147

SP - 963

EP - 966

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 5

ER -